Drugs that induce a distinctive, subjective altered state of consciousness—broadly referred to as “Psychedelics”— stand to revolutionize the treatment of mental disorders.

At present only one such drug, Ketamine, is FDA-approved for human use and, therefore, can be prescribed (off-label) to treat mental illness. However, many more psychedelics are under development including MDMA and Psilocybin, which have been given “fast track” designation by the FDA.

In this presentation, Dr. Feifel will provide an overview of these drugs, their approval status and how they will be used to impact on the treatment of mental illness.

This virtual event is FREE, but in order to attend or receive a link to the recording, YOU MUST REGISTER HERE:
https://us02web.zoom.us/meeting/register/tZEtd-2pqzkjHdEDpNYGQWfOQ6AslCtMqsEC

After you register, you will be emailed a link to the event.
We will also send you a reminder via email on the morning of the event.

*****Please consider making a voluntary contribution of $10-$15-$25 or more – via our donation form so that we may continue bringing you quality KSG events free of charge.******

About David Feifel, MD, PhD

Dr. David Feifel is a Professor Emeritus of Psychiatry at UC San Diego. He received his MD and PhD (Neurobiology) from the University of Toronto and he is certified in General Psychiatry as well as Behavioral Neurology and Neuropsychiatry.

The focus of Dr. Feifel’s career has been on advancing the treatment of mental illness. He has published more than 130 peer-reviewed research papers and his work has been featured in many publications and media resources such as the New York Times, Time, NPR, The Washington Post, Popular Science, Scientific American. In 2008, while at UCSD, he established the world’s first clinical ketamine infusion program to treat depression, and in 2017, he founded Kadima Neuropsychiatry Institute, in La Jolla, California, focusing on administering and innovating advanced treatments such as TMS, ketamine and psychedelic therapies. Among the ongoing or upcoming projects at KADIMA are clinical trials of psilocybin, LSD and DMT for psychiatric disorders.

David Feifel, MD, PhD
Professor Emeritus  of Psychiatry, University of  California, San Diego
Director,  Kadima Neuropsychiatry Institute
Certification::General Psychiatry / Behavioral Neurology and Neuropsychiatry
linkedin.com/in/davidfeifel

3252 Holiday Ct, St. 112, La Jolla, CA, 92037
Phone: 858-412- 4130
kadimanp.com

This virtual event is FREE, but in order to attend or receive a link to the recording, YOU MUST REGISTER HERE:
https://us02web.zoom.us/meeting/register/tZEtd-2pqzkjHdEDpNYGQWfOQ6AslCtMqsEC

After you register, you will be emailed a link to the event.
We will also send you a reminder via email on the morning of the event.

*****Please consider making a voluntary contribution of $10-$15-$25 or more – via our donation form so that we may continue bringing you quality KSG events free of charge.******